Clinical Trials Logo

Other Solid Tumors clinical trials

View clinical trials related to Other Solid Tumors.

Filter by:

NCT ID: NCT02711345 Terminated - Melanoma Clinical Trials

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Start date: April 15, 2016
Phase: Phase 1
Study type: Interventional

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

NCT ID: NCT02709889 Terminated - Glioblastoma Clinical Trials

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Start date: September 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

NCT ID: NCT02607813 Terminated - Ovarian Cancer Clinical Trials

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Start date: January 18, 2016
Phase: Phase 1
Study type: Interventional

A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.

NCT ID: NCT02573259 Completed - MELANOMA Clinical Trials

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Start date: February 10, 2016
Phase: Phase 1
Study type: Interventional

Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.

NCT ID: NCT02404441 Completed - Melanoma Clinical Trials

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Start date: April 27, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent to adult patients with solid tumors. By blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, PDR001 inhibits the PD-1 immune checkpoint, resulting in activation of an antitumor immune response by activating effector T-cells and inhibiting regulatory T-cells.

NCT ID: NCT00106145 Completed - Clinical trials for Advanced Breast Cancer

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Start date: April 2005
Phase: Phase 1
Study type: Interventional

An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.

NCT ID: NCT00064636 Terminated - Clinical trials for Advanced Non-Small Cell Lung Cancer

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Start date: December 2002
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate how safe VELCADE (PS-341) is when given with Taxotere (Docetaxel) to patients with non-small cell lung cancer or other solid tumors, and also to see what effects (good and bad) it has on you and your cancer.